X4 Pharmaceuticals announced that its Phase 3 4WARD trial for chronic neutropenia is now active at around 90% of targeted sites, with expected full enrollment by Q3 or Q4 of 2025 and top-line data ...

Background Autoimmune neutropenia (AIN) is the main cause of chronic neutropenia in children, but its infectious consequences ...

X4 Pharmaceuticals announced the acceptance of two abstracts for presentation at the upcoming European Hematology Association Congress regarding the positive results from their Phase 2 trial of ...

BOSTON, May 14, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (XFOR) (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced the ...

BOSTON, Dec. 04, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced its upcoming ...

Reducing overall headcount by 43 people (approximately 30% of X4 employees), which includes discontinuing research efforts and closing the company’s facility in Vienna, Austria, as well as pausing pre ...

Autoimmune neutropenia is a multifaceted condition in which the immune system erroneously produces autoantibodies that target neutrophils, leading to their premature destruction and a consequential ...

BOSTON, June 10, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that the U.S. Food ...

Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221) Empiric antifungal therapy (EAT) is ...